Yellow Tomorrow

Nuclear energy where you least expect it

The promise of Targeted Alpha Therapy

Targeted Alpha Therapy is an innovative technology that combines lead-212 with biological molecules (peptides, antibodies) to target cancer cell receptors or antigens. Targeted Alpha Therapy thus makes it possible to recognize and destroy cancer cells selectively while limiting the impact on the surrounding healthy cells.

Increased lead-212 supply capacity

Orano Med has increased its lead-212 manufacturing capacity fivefold using thorium nitrate from Orano’s former mining activities, having doubled the surface areas of its Maurice Tubiana Laboratory in Bessines. This milestone embodies Orano Med’s commitment to producing radioisotopes in sufficient quantities and at a level of purity in line with pharmaceutical standards to enable the development and marketing of cancer treatments.

The next advances for Orano Med

Orano Med’s ambition is to develop a robust portfolio of cancer treatments that combine the properties of lead-212 with targeting molecules. To achieve this, the company is currently working on a dozen developments either alone or in partnership with other French and international biotechnology and pharmaceutical companies.

  • 2005Discovery of the process for extracting lead-212
  • 2009Founding of Orano Med
  • 2011
    Acquisition of Macrocyclics, a company specializing in the production and development of chelating agents for nuclear medicine
  • 2012 to 2014First clinical trial of alpha therapy using lead-212
  • 2013Inauguration of the Maurice Tubiana Laboratory (LMT) in Bessines-sur-Gartempe
  • 2016Inauguration of Orano Med’s 2nd  unit in Plano, Texas (DDPU)
  • 2018-2020Beginning of clinical trials for a treatment against neuroendocrine tumors
  • 2019Extension  of lead-212 production capacities in France and the United States
  • 2020Commissioning of the extended LMT laboratory and R&D center in Bessines-sur-Gartempe
  • 2021Alphamedix™, a treatment for neuroendocrine tumors, enters Phase II clinical trials